Immunocore Holdings plc
IMCR · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -5.43 | 0.12 | -0.61 | 0.04 |
| FCF Yield | -0.28% | 1.62% | 0.01% | -1.19% |
| EV / EBITDA | 331.97 | -238.59 | 144.86 | -95.05 |
| Quality | ||||
| ROIC | -0.77% | -1.63% | -0.34% | -2.33% |
| Gross Margin | 99.51% | 98.94% | 99.11% | 99.61% |
| Cash Conversion Ratio | 25.18 | -2.52 | 0.09 | 0.59 |
| Growth | ||||
| Revenue 3-Year CAGR | 18.50% | 18.93% | 20.19% | 24.71% |
| Free Cash Flow Growth | -120.37% | 18,549.64% | 100.78% | -186.38% |
| Safety | ||||
| Net Debt / EBITDA | -109.80 | 8.04 | -4.30 | 1.51 |
| Interest Coverage | -2.36 | -4.83 | -1.20 | -2.79 |
| Efficiency | ||||
| Inventory Turnover | 0.09 | 0.19 | 0.12 | 0.06 |
| Cash Conversion Cycle | -2,969.40 | -1,528.22 | -2,354.79 | -5,271.21 |